Kadmon Holdings, Inc.
NYSE: KDMN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Harlan Waksal
- Employees
- 127
- Headquarters
- New York City, United States
- IPO year
- 2016
- Website
- http://www.kadmon.com
Loading KDMN…
Loading profile data…Frequently asked questions about KDMN
What does Kadmon Holdings, Inc. (KDMN) do?
Kadmon Holdings operates as a biopharmaceutical firm, focusing on the discovery, development, and commercialization of small molecule compounds and biologics, primarily to address inflammatory and fibrotic disorders. Its leading therapeutic asset is KD025, an orally administered selective inhibitor of rho-associated coiled-coil kinase 2 (ROCK2),...
Where does KDMN trade?
Kadmon Holdings, Inc. (KDMN) trades on the New York Stock Exchange.
What sector is KDMN in?
Kadmon Holdings, Inc. (KDMN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kadmon Holdings, Inc.?
Harlan Waksal is the chief executive officer of Kadmon Holdings, Inc. (KDMN).
Where is Kadmon Holdings, Inc. headquartered?
Kadmon Holdings, Inc. is headquartered in United States.
Does KDMN pay a dividend?
Kadmon Holdings, Inc. (KDMN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KDMN go public?
Kadmon Holdings, Inc. (KDMN) completed its initial public offering in 2016.